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Abstract 
Background: Early detection and therapy of the obese adolescent with a family history of type 2 diabetes may 
interrupt the cycle of weight gain and insulin resistance that leads to glucose intolerance in adulthood. Materials & 
Methods: The objective of our study was to observe the effect of metformin and voglibose on BMI, as it provides a 
simple and convenient anthropometric index for classification of obesity. 60 non diabetic obese subjects were 
selected on the basis of inclusion and exclusion criteria, and divided into three groups of 20 subjects each. The first 
group received metformin 500 mg BD, second group received voglibose 0.3 mg and the third group received a 
combination of metformin 500 mg and voglibose 0.3mg. For the comparison we applied paired and unpaired t test. 
Paired t test was applied for intra group comparison and unpaired t test was applied for inter group comparison. 
Results: After six months of treatment with Metformin 500 mg BD alone, Voglibose 0.3mg BD alone and 
Metformin 500 mg with Voglibose 0.3 mg BD in combination, all three groups showed statistically significant 
reduction in BMI values from baseline. When we compared results of metformin group with voglibose group there 
was no statistically significant difference. But when we compared results of metformin alone with metformin and 
voglibose combination and voglibose alone with metformin and voglibose combination, the combination group 
showed statistically significant reduction in BMI base line values. Conclusion: Therefore, it can be concluded that 
Metformin + Voglibose combination is very effective in reducing body weight, but further long term studies with 
large sample size are needed to assess the safety and efficacy of Metformin+ Voglibose combination in treatment of 
obesity in non-diabetic population. 
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Introduction  
Throughout most of the human history, obesity has 
been viewed as a sign of health and prosperity. But 
now it has been termed as an epidemic and social 
burden, with increasing prevalence worldwide.[1] 
Obesity is also defined as an abnormal growth of the 
adipose tissue due to an enlargement of fat cell size 
(hypertrophic obesity) or an increase in fat cell number 
(hyper plastic obesity) or a combination of both or is 
defined “as a condition of abnormal or excessive fat 
accumulation in adipose tissue, to the extent that health 
may be impaired to produce adverse health 
consequences and is associated with increased 
morbidity and mortality”. [2-3]  
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According to the World Health Organization estimates, 
1.6 billion adults (aged 15 years and above) were 
overweight and 400 million were obese in 2005 and the 
figures are predicted to rise to 2.3 billion overweight 
and over 700 million obese adults by 2015.[4] 
Surprisingly, obesity is often neglected, though it is 
associated with a serious, life-threatening 
complications like increasing risk of cardio-metabolic 
illness.[5,6]  According to National Family Health 
Survey (NFHS)-3 prevalence of overweight or obesity 
in India  is 12.1% in males and 16% in females, and in 
Maharashtra it is 15.9% in Males & 18.1% in 
females.[7]   
Body mass index (BMI) provides a simple and 
convenient anthropometric index for classification of 
obesity. The World Health Organization (WHO), the 
US Preventive Services Task Force and the 
International Obesity Task Force define overweight “as 
a BMI between 25.0 to 29.9 kg/m2 and obesity as a 
BMI 30.0 kg/m2”.[8, 9] 
Table 1: Body Mass Index Classification[10] 
Parameter WHO Criteria Indian Criteria 
Normal 18.5-24.9 Kg/m2 18.0-22.9 Kg/m2 
Over- weight 25.0-29.9 Kg/m2 23.0-24.9 Kg/m2 
Obese > 30 Kg/m2 > 25 Kg/m2 
Therapeutic approach for a non-diabetic obese patient 
starts with comprehensive lifestyle management i.e. 
very low calorie diet, physical activity and behavior 
modification and if needed anti-obesity drugs. Bariatric 
surgery is suggested for those who are at greater risk of 
obesity. There are many examples of drugs used 
historically for weight loss that have been removed 
owing to significant side effects, like sibutramine & 
rimonabant. FDA approved orlistat as an anti-obesity 
drug in 1999. It reduces intestinal fat absorption by 
inhibiting pancreatic lipase. Orlistat is notorious for its 
gastrointestinal side effects which include steatorrhea. 
Though they are the most frequently reported adverse 
effect of the drug, but they tend to decrease with time. 
FDA approved few new anti obesity as adjunctive 
therapy for chronic weight management: lorcaserin 
approved in 2012; and phentermine/topiramate 
extended-release formulation also approved in 
2012.[11] 
Metformin, the biguanide, is most widely used for the 
treatment of type 2 Diabetes Mellitus (T2DM). In 
diabetic patients, it suppresses endogenous glucose 
production and may also act as an insulin sensitizer. It 
also helps diabetic patients to lose weight or at least 
keep their weight stable.[12,13] The weight loss effects 
have been attributed by lipolytic and anorectic effects; 
also suppressing glucose production by liver.[13] 
Metformin activates AMP-activated protein kinase 
(AMPK), a liver enzyme that plays an important role in 
insulin signaling, whole body energy balance, and the 
metabolism of glucose and fats. Recent studies 
suggests that the effect of metformin on AMP-activated 
protein kinase (AMPK) dependent lipolysis in 
adipocytes may lead to lower plasma levels of fatty 
acids and improve adipose tissue function.[14] 
Voglibose is the recent alpha glycosidase inhibitor. 
Though voglibose has similar efficacy to acarbose, it 
has much weaker effect on alpha-amylase when given 
in a pharmacological dose. Hence, it has better 
tolerability.[15,16] It has shown strong anti-obesity and 
anti-diabetic activities and has been found to 
significantly reduce postprandial blood glucose 
concentration and weight in some animals.[17] It 
delays the digestion and absorption of carbohydrates, 
thereby inhibiting postprandial hyperglycemia. 
Administration of voglibose, increases the secretion of 
glucagon-like peptide (GLP)-1. GLP 1 is an incretin 
type of hormone, which causes early satiety.  Also, it 
decreases plasma dipeptidyl peptidase-4 (DPP-4) 
activity.[18] Study by  Xiaoling Cai et al shows weight 
reduction with Alpha Glucosidase inhibitors on Type 2 
Diabetes Patients.[19]  An animal study done by Hyun 
Ju Do shows weight reduction in non diabetic mice 
with voglibose.[20] 
Some studies have revealed that there is significant 
weight reduction in non diabetic subjects with 
metformin.[21] Also some studies have revealed 
weight reduction with voglibse in T2DM patients.  In a 
study done on non-diabetic animals with obesity, there 
was weight reduction with voglibose, considering the 
findings of above studies; we have undertaken this 
study to see the effect of voglibose on weight in non 
diabetic subjects.[22]   
At present, no clinical studies have been reported of 
metformin and voglibose in head to head comparison 
for non-diabetic obesity.  Therefore, the present study 
was planned to compare and evaluate the effect of 
metformin and voglibose on BMI in non-diabetics 
obese individuals. 
Material and Methods 
Present study was carried out in the Department of 
General Medicine in collaboration with the Department 
of Pharmacology at MGM Medical College and 
hospital, Aurangabad between September 2013 to 
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February 2014. The subjects enrolled for this study 
were selected after screening for HbA1c according to 
the inclusion and exclusion criteria. Written informed 
consent was obtained from each patient. Age group of 
20-60 years of either sex, obese or overweight 
determined by a BMI of> 25 kg/m2 and willing to 
participate were included in the study. Patients with 
HbA1c <5.7% or  diabetic patients, pregnant and 
lactating women, subjects allergic to drugs & sensitive 
to drugs, subjects concurrently taking other medication 
which is known to affect the obesity and patients with 
gastrointestinal disorders like inflammatory bowel 
disease, deranged liver, kidney and thyroid function 
test were excluded. Institutional Ethics Committee 
permission and study participant’s consent was taken.  
Study Drugs: Tablet metformin (500 mg) and tab 
voglibose 0.3mg 
Study Groups  
Group A: Voglibose    
Group B: Metformin      
Group C: Combination (Voglibose+ 
Metformin) 
   Volunteers were assessed at baseline for HbA1c for 
screening of non-diabetic subjects. Healthy non-
diabetic obese subjects were enrolled and assessed at 
baseline and at end of study for body mass index. After 
general physical examination of study participants’ 
baseline investigations like HbA1c, FBG and PPBG 
were estimated. The statistical evaluation was done by 
Student’s t-test with the help of SPSS (Statistical 
Package for Social Service version 19) value less than 
p<0.05 was taken as significant. 
Results 
 Sixty non-diabetic obese subjects (n=60) volunteers 
completed the study.  Evaluation was done at baseline 
and after 6 month. All the groups were matched in 
baseline characteristics i.e. age, sex and weight. The 
BMI decreased significantly when compared to 
baseline value in all three groups. For the result and 
calculation we applied student t test, both paired and 
unpaired. Intra-group comparison of voglibose and 
metformin at baseline and after six months was found 
to be significant but a highly significant result was 
found in combination group (voglibose+ metformin) 
[Table 2/Fig. 1]. 
Metformin and Voglibose 
Inter group comparison between group metformin and 
voglibose showed no statistical difference in BMI 
(0.1±2.37) when compared by using unpaired t test and 
was found to be statistically non-significant with a p 
value > 0.05 [Table 3].  
Metformin alone and in combination group 
(voglibose and metformin) 
Inter group comparison between metformin group and 
combination group showed statistical difference in 
BMI (1.4 ± 1.97) when compared by using unpaired t 
test and was found to be statistically significant with a 
p value < 0.05 [Table 3].  
Voglibose alone and in combination (Voglibose and 
Metformin) 
Inter group comparison between Voglibose group and 
combination group showed statistical difference in 
BMI (1.5± 2.28) when compared by using unpaired t–
test and was found to be statistically significant with a 
p value < 0.05 [Table 3].  
Adverse Effects  
Most common adverse drug reaction reported in all the 
three groups were related to gastrointestinal 
disturbances. In the 2 patients (10%) in metformin 
group had shown adverse drug reactions. In Voglibose 
group had 4 patients (20%) and in combination group 5 
patients (25%). In Metformin group, adverse drug 
reaction seen was bloating of abdomen in 2 patients 
(10%).   With voglibose group, gastrointestinal adverse 
drug reaction seen were nausea in 1 patient (5%), 
flatulence in 2 patients (10%), and diarrhea in 1 patient 
(5%). In combination group, adverse drug reaction seen 
were, nausea in 1 patient (5%), bloating of abdomen in 
2 patients (10%), diarrhoea in 1 patient (5%) and 
abdominal pain in 1 patient (5%) [Table 4].  
Table 2: Changes of BMI in study groups [metformin and voglibose alone and in combination before and 
after therapy] 
                                                   
 
Group 
BMI  
P value Mean value  ± SD 
Before therapy After Therapy Mean difference 
A 28.55± 2.19 27.84±2.08 1.26±1.07 0.00 
B 28.84±2.73 27.41±2.83 1.44±0.68 0.00 
C 28.94±2.005 25.93±1.86 3.00±1.03 0.00 
Note: P< 0.05**: Statistically significant , P <0.001***: Statistically highly significant 
Group A: Metformin, Group B: Voglibose,   Group C: Combination (voglibose+ metformin) 
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Figure 1: Showing comparison of baseline values of BMI before and after therapy in three groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3:  Unpaired t- test for comparison of BMI 
 
Groups Mean Difference ± SD P value 
A Vs. B 0.1±2.37 0.88 
A Vs. C 1.4 ± 1.97 0.035** 
B Vs. C 1.5 ± 2.28 0.048** 
 (Note: P> 0.05*: Not Statistically significant, P< 0.05**: Statistically significant) 
 
Table 4: Comparison of ADR’s in treatment with metformin, voglibose and combination groups 
ADR’s Group A Group B Group C 
Nausea - 5% 5% 
Abdominal bloating 10% - 10% 
Flatulence - 10% - 
Diarrhea - 5% 5% 
Abdominal Pain - - 5% 
Total 10% 20% 25% 
 
Discussion 
Both the study drugs are widely used in the treatment 
of diabetic patients. Some studies have revealed 
effectiveness of metformin in weight reduction, [21] 
not only in diabetics but, also in non-diabetic patients 
also. Similarly, administration of voglibose in diabetic 
patients has shown weight reduction. Another study 
involving use of voglibose in non diabetic obese 
animals showed weight reduction.[18] Due to above 
considerations, this study was undertaken. Moreover, at 
present no clinical studies have been reported on 
metformin and voglibose in head to head comparison 
for non-diabetic obesity.  Therefore, the present study 
was planned. 
When we applied paired t-test for metfomin group, it 
showed significant reduction in BMI after six months 
of treatment as compared to baseline values. These 
findings are similar to a study conducted by C. Seifarth 
et al on non diabetic obese (n= 154) patients with a 
body mass index ≥27 kg/m2 showed mean weight loss 
in the metformin treated group of 5.8±7.0 kg 
(5.6±6.5%) over 6 months.[21] Probable mechanisms 
of metformin for weight reduction is its lipolytic and 
anorectic action.22 Other possible mechanism is its 
actions it increases GLP 1.  Also weight loss through 
AMP-activated protein kinase (AMPK) lead to lower 
plasma fatty acid level and improve adipose tissue 
function.[23, 24] 
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In TODY Study to manage  T2DM in youth showed 
gastrointestinal disturbances were most common 
adverse event (41%) in metformin treatment group.[16] 
In our study though drug was well tolerated as there 
was only one type of ADR reported i.e. the bloating of 
abdomen in 2 patients.[25]  
Similarly, there was significant reduction in BMI 
values from baseline in Voglibose group (0.3 mg BD) 
in our group after six months of treatment. (1.44 ±0.68) 
P < 0.00. Study by Xiaoling Cai et al [19] showed 
weight reduction from baseline was significantly more 
with voglibose treatment (n= 216) compared with 
placebo (n= 210) in Asians (WMD, 21.00 kg;). Also 
another study done by Hyun Ju Do, exhibited weight 
reduction in non diabetic obese mice with 
voglibose.[26]The probable weight reduction 
mechanism is increase in the secretion of glucagon-like 
peptide (GLP)-1, causing early satiety. Also it delays 
the digestion and absorption of carbohydrates, thereby 
inhibiting postprandial hyperglycemia.[18] In a Study 
by Iwamoto Y et al in Japanese patient with T2DM, the 
most common drug related ADRs with voglibose group 
were gastrointestinal disorders with an incidence of 
32.8%167 in our study ADRs with voglibose group 
were, Nausea in 1 patient, flatulence in 2 patients, and 
diarrhoea in 1 patient.[27]  
In our study we found significant weight reduction 
with combination group which is more as compared to 
other groups; this is because of additive effect of 
combination of Metformin with Voglibose.  In this 
group, ADRs were seen i.e. nausea in 1 patient, 
bloating of abdomen in 2 patients, diarrhoea in 1 
patient and abdominal pain in 1 patient.  
 
Conclusion  
After six months of treatment with Metformin 500mg 
BD alone, Voglibose 0.3mg BD alone, and Metformin 
500mg with Voglibose 0.3mg BD in combination, all 
three groups showed statistically significant reduction 
in BMI values from baseline. When we compared 
results of metformin group with voglibose group there 
was no statistically significant difference. But when we 
compared results of metformin alone with metformin 
and voglibose combination and voglibose alone with 
metformin and voglibose combination, the combination 
group showed statistically significant reduction in BMI 
base line values.    
There was only a single ADR associated with 
Metformin group i.e. bloatting of abdomen in 2 
patients. In Voglibose group, there was Nausea in 1 
patient, flatulence in 2 patients and diarrhea in 1 
patient. While in the combination group, ADRs were 
nausea in 1 patient, bloting of abdomen in 2 patients, 
diarrhea in 1 patient and abdominal pain in 1 patient.  
Although ADR’s associated with the combination of 
Voglibose and Metformin are comparatively more but 
they are not serious and subside with time, therefore it 
can be concluded that, the use of Metformin and 
Voglibose in combination has greater efficacy in 
reducing the BMI in non- diabetic obese subjects than 
drugs when given alone. Therefore, it can be concluded 
that Metformin + Voglibose combination is very 
effective in reducing body weight, but further long 
term studies with large sample size are needed to assess 
the safety and efficacy of Metformin+ Voglibose 
combination in treatment of obesity in non-diabetic 
population 
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